Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | KDM1A | O60341 | 7/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | ALPG | P10696 | 1/20 | 0.40 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL23327254 | 0.89 | MRGPRX4 (0.45) | L3MBTL1MAPTLMNAMRGPRX4LRRK2 | |
| SCHEMBL435851 | 0.85 | MAPT (0.49) | L3MBTL1KDM1AMAPTMAPK1TDP1 | |
| SCHEMBL31658801 | 0.84 | NPC1 (0.45) | — | |
| SCHEMBL27167092 | 0.80 | LMNA (0.44) | L3MBTL1KDM1AMAPTLMNAMRGPRX4 | |
| SCHEMBL27167035 | 0.80 | ALPG (0.45) | L3MBTL1MAPTLMNAMRGPRX4ALPG | |
| SCHEMBL30434028 | 0.80 | L3MBTL1 (0.45) | L3MBTL1KDM1AMAPTMAPK1TDP1 | |
| SCHEMBL21408282 | 0.80 | L3MBTL1 (0.45) | L3MBTL1KDM1AMAPTMAPK1TDP1 | |
| SCHEMBL31482934 | 0.80 | L3MBTL1 (0.42) | L3MBTL1KDM1AMAPTMAPK1TDP1 | |
| SCHEMBL23327663 | 0.79 | MRGPRX4 (0.44) | L3MBTL1MAPTLMNAMRGPRX4ALPG | |
| SCHEMBL451750 | 0.79 | MAPT (0.46) | L3MBTL1KDM1AMAPTMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111971287-B | Macrocyclic compounds as TRK kinase inhibitors | 重庆复尚源创医药技术有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-11555042-B2 | Macrocyclic compounds as TRK kinases inhibitors | FOCHON BIOSCIENCES, LTD. (CN) | 2023-01-17 | — | — | US | disclosed |
| US-20210139506-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASES INHIBITORS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2021-05-13 | — | — | US | disclosed |
| US-20210139506-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASES INHIBITORS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2021-05-13 | — | — | US | disclosed |
| CN-111971287-A | Macrocyclic compounds as TRK kinase inhibitors | 重庆复创医药研究有限公司 | 2020-11-20 | — | — | CN | disclosed |
| WO-2019184955-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASES INHIBITORS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2019-10-03 | — | — | WO | disclosed |
| US-20150073136-A1 | PYRAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| US-8889692-B2 | Pyrazinone derivatives, pharmaceutically acceptance salts thereof and their uses | ASTRAZENECA AB (SE) | 2014-11-18 | — | — | US | disclosed |
| EP-2170848-B1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | ASTRAZENECA AB (SE) | 2014-10-22 | — | — | EP | disclosed |
| US-20130012523-A1 | PYRAZINONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES | BROUGH STEPHEN (GB) | 2013-01-10 | — | — | US | disclosed |
| US-8299246-B2 | N-cyclopropyl-3-fluoro-5-[3-[[1-[2-[2- [(2-hydroxethyl)amino] ethoxy]phenyl] cyclopropyl] amino]-2-oxo-1 (2H)-pyrazinyl]-4-methyl-benzamide, or pharmaceutically acceptable salts thereof and their uses | ASTRAZENECA AB (SE) | 2012-10-30 | — | — | US | disclosed |
| US-20120214822-A1 | N-CYCLOPROPYL-3-FLUORO-5-[3-[[1-[2-[2- [(2-HYDROXETHYL)AMINO] ETHOXY]PHENYL] CYCLOPROPYL] AMINO]-2-OXO- 1 (2H)-PYRAZINYL]-4-METHYL-BENZAMIDE, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES | ASTRAZENECA AB (SE) | 2012-08-23 | — | — | US | disclosed |
| US-8163905-B2 | Compounds and their uses 708 | ASTRAZENECA AB (SE) | 2012-04-24 | — | — | US | disclosed |
| US-20120065214-A1 | COMPOUNDS AND THEIR USES 708 | ASTRAZENECA AB (SE) | 2012-03-15 | — | — | US | disclosed |
| EP-2170848-A1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | AstraZeneca AB (SE) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009001132-A1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139506-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASES INHIBITORS | PLK2, ERBB3, DMPK | L3MBTL1 2668/4885KDM1A 2864/4885MAPT 1273/4885 |
| US-20120065214-A1 | COMPOUNDS AND THEIR USES 708 | CYP3A7, CYP2C8, CYP2C18 | L3MBTL1 4827/4885KDM1A 2265/4885MAPT 2316/4885 |
| US-20120214822-A1 | N-CYCLOPROPYL-3-FLUORO-5-[3-[[1-[2-[2- [(2-HYDROXETHYL)AMINO] ETHOXY]PHENYL] CYCLOPROPYL] AMINO]-2-OXO- 1 (2H)-PYRAZINYL]-4-METHYL-BENZAMIDE, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-0, CYP3A5 | L3MBTL1 3952/4885KDM1A 259/4885MAPT 3682/4885 |
| US-11555042-B2 | Macrocyclic compounds as TRK kinases inhibitors | PLK2, ERBB3, DMPK | L3MBTL1 2668/4885KDM1A 2864/4885MAPT 1273/4885 |
| US-20150073136-A1 | PYRAZINONE DERIVATIVES | CYP3A7, CYP3A4, CYP2D6 | L3MBTL1 4427/4885KDM1A 2415/4885MAPT 2955/4885 |
| US-20130012523-A1 | PYRAZINONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES | CYP3A7, CYP3A5, CYP2C19 | L3MBTL1 4142/4885KDM1A 2940/4885MAPT 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.